Abstract
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. As opposed to previously tested neprilysin inhibitors, sacubitril/valsartan represents a more effective method in reducing morbidity and mortality in heart failure, while preserving a safety profile comparable to well-established, standard, angiotensin-converting enzyme inhibitor's therapy.
Keywords:
heart failure; neprilysin; sacubitril/valsartan.
MeSH terms
-
Aminobutyrates / adverse effects
-
Aminobutyrates / pharmacokinetics
-
Aminobutyrates / therapeutic use*
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / pharmacokinetics
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Animals
-
Biphenyl Compounds
-
Drug Combinations
-
Heart Failure / diagnosis
-
Heart Failure / drug therapy*
-
Heart Failure / mortality
-
Heart Failure / physiopathology
-
Humans
-
Neprilysin / antagonists & inhibitors*
-
Neprilysin / metabolism
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / pharmacokinetics
-
Protease Inhibitors / therapeutic use*
-
Recovery of Function
-
Renin-Angiotensin System / drug effects*
-
Tetrazoles / adverse effects
-
Tetrazoles / pharmacokinetics
-
Tetrazoles / therapeutic use*
-
Treatment Outcome
-
Valsartan
Substances
-
Aminobutyrates
-
Angiotensin II Type 1 Receptor Blockers
-
Biphenyl Compounds
-
Drug Combinations
-
Protease Inhibitors
-
Tetrazoles
-
Valsartan
-
Neprilysin
-
sacubitril and valsartan sodium hydrate drug combination